Victory Capital Management Inc. cut its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 17.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 830,100 shares of the company's stock after selling 172,612 shares during the quarter. Victory Capital Management Inc. owned approximately 1.54% of LivaNova worth $42,949,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Arizona State Retirement System boosted its position in shares of LivaNova by 1.8% in the third quarter. Arizona State Retirement System now owns 15,309 shares of the company's stock valued at $810,000 after acquiring an additional 264 shares during the period. Headlands Technologies LLC grew its position in LivaNova by 33.3% in the 4th quarter. Headlands Technologies LLC now owns 1,807 shares of the company's stock worth $93,000 after purchasing an additional 451 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of LivaNova by 2.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,202 shares of the company's stock worth $1,438,000 after purchasing an additional 544 shares during the period. Kennedy Capital Management LLC raised its position in shares of LivaNova by 0.3% during the third quarter. Kennedy Capital Management LLC now owns 301,078 shares of the company's stock valued at $15,921,000 after buying an additional 888 shares during the last quarter. Finally, Wedge Capital Management L L P NC lifted its stake in shares of LivaNova by 1.4% in the fourth quarter. Wedge Capital Management L L P NC now owns 73,845 shares of the company's stock valued at $3,821,000 after buying an additional 1,049 shares during the period. Institutional investors own 97.64% of the company's stock.
LivaNova Price Performance
Shares of NASDAQ:LIVN traded down $1.55 during trading on Monday, reaching $62.60. The stock had a trading volume of 668,561 shares, compared to its average volume of 652,974. The stock has a market capitalization of $3.39 billion, a PE ratio of -104.33 and a beta of 0.92. LivaNova PLC has a 52 week low of $42.75 and a 52 week high of $64.47. The business's 50-day moving average price is $54.84 and its 200 day moving average price is $51.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.17 and a quick ratio of 2.71.
LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.45 by $0.28. The firm had revenue of $294.90 million during the quarter, compared to the consensus estimate of $278.17 million. LivaNova had a positive return on equity of 13.59% and a negative net margin of 2.68%. The business's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS. As a group, equities analysts predict that LivaNova PLC will post 3.01 earnings per share for the current year.
Analysts Set New Price Targets
LIVN has been the topic of several research reports. Needham & Company LLC restated a "buy" rating and set a $72.00 price target on shares of LivaNova in a research note on Wednesday, May 1st. Barclays raised their target price on LivaNova from $57.00 to $61.00 and gave the stock an "equal weight" rating in a research report on Monday, February 26th. Robert W. Baird boosted their price target on shares of LivaNova from $58.00 to $66.00 and gave the company a "neutral" rating in a report on Thursday. Mizuho increased their price objective on shares of LivaNova from $75.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday. Finally, StockNews.com upgraded shares of LivaNova from a "hold" rating to a "buy" rating in a research report on Thursday, April 25th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $66.20.
Get Our Latest Stock Report on LIVN
LivaNova Profile
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Articles
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
